Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Chronic glomerular diseases, associated with renal failure and cardiovascular morbidity, represent a major health issue. However, they remain poorly understood. Here we have reported that tightly controlled mTOR activity was crucial to maintaining glomerular podocyte function, while dysregulation of mTOR facilitated glomerular diseases. Genetic deletion of mTOR complex 1 (mTORC1) in mouse podocytes induced proteinuria and progressive glomerulosclerosis. Furthermore, simultaneous deletion of both mTORC1 and mTORC2 from mouse podocytes aggravated the glomerular lesions, revealing the importance of both mTOR complexes for podocyte homeostasis. In contrast, increased mTOR activity accompanied human diabetic nephropathy, characterized by early glomerular hypertrophy and hyperfiltration. Curtailing mTORC1 signaling in mice by genetically reducing mTORC1 copy number in podocytes prevented glomerulosclerosis and significantly ameliorated the progression of glomerular disease in diabetic nephropathy. These results demonstrate the requirement for tightly balanced mTOR activity in podocyte homeostasis and suggest that mTOR inhibition can protect podocytes and prevent progressive diabetic nephropathy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gödel et al. [16] suggested that mTOR signaling plays a role in podocyte homeostasis.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“The decrease in activity of neurofibromin in NF1 might also be associated with LPG which is a glomerular disease, and contribute to the development of LPG as an additional factor.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [16]
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
In the citing paper
“However, the side effects of long-term or complete mTORC1 inhibition in kidney cells have been well-recognized, such as the early onset of proteinuria caused by specific inhibition of mTORC1 activity in podocytes in mice and the disruption of kidney tubular homeostasis caused by specific inhibition of mTORC1 activity in kidney tubular cells in mice51,80.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [51]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationA global double-fluorescent Cre reporter mouse
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., & Luo, L. (2007) · genesis · doi:10.1002/dvg.20335 · Cited by 3,491
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Research works printed but not linked: 5
- Estacio, 2001, Adv Intern Med., 46, 359
- Munivenkatappa, 2010, Histol Histopathol., 25, 189
- Weening, 1987, Am J Pathol., 129, 64
- Artacho-Perula, 1993, Lab Invest., 68, 56
- Souster, 1980, J Anat., 130, 595
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Furthermore, recent studies have shown that either deletion or upregulation of components of the mTOR pathway, including the mTOR complexes mTORC1 and mTOR2 (210, 267), contribute to the development of diabetic nephropathy.”
BackgroundThomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Shimano, H., & Sato, R. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.91 · Cited by 1,174
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
Self-citationMolecular mechanisms of diabetic kidney disease
Reidy, K., Kang, H. M., Hostetter, T., & Susztak, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72271 · Cited by 909
“Decreased activation of mTORC1 protected against DKD in mouse models (77, 78), but complete deletion of mTOR caused glomerular disease (78).”
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Self-citationObesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
D'Agati, V. D., Chagnac, A., de Vries, A. P. J., Levi, M., Porrini, E., Herman-Edelstein, M., & Praga, M. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.75 · Cited by 716
Mitochondrial dysfunction in diabetic kidney disease
Forbes, J. M., & Thorburn, D. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.9 · Cited by 634
Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 555
“In podocytes, mTORC1 plays a role in the development of diabetic nephropathy, whereas mTORC2 appears to have a minor role (Gödel et al., 2011; Inoki et al., 2011).”
BackgroundSelf-citationEmerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases
Cybulsky, A. V. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.129 · Cited by 526
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
Self-citationCell Biology and Pathology of Podocytes
Greka, A., & Mundel, P. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153238 · Cited by 518
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
de Vries, A. P. J., Ruggenenti, P., Ruan, X. Z., Praga, M., Cruzado, J. M., Bajema, I. M., D'Agati, V. D., Lamb, H. J., Barlovic, D. P., Hojs, R., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70065-8 · Cited by 500
The diverse functionality of NQO1 and its roles in redox control
Ross, D., & Siegel, D. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101950 · Cited by 499
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
Cellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Self-citationAKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms
He, L., Wei, Q., Liu, J., Yi, M., Liu, Y., Liu, H., Sun, L., Peng, Y., Liu, F., Venkatachalam, M. A., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.06.030 · Cited by 448
Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog
Edeling, M., Ragi, G., Huang, S., Pavenstädt, H., & Susztak, K. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.54 · Cited by 430
Self-citationThe cardio-renal-metabolic connection: a review of the evidence
Marassi, M., & Fadini, G. P. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01937-x · Cited by 386
“It has been demonstrated that, in glomerular podocytes, the cells responsible for the integrity of the glomerular basement membrane (GBM) and the correct functioning of the glomerular capillary loop, mTOR activation recapitulates many characteristics of DKD, such as proteinuria and mesangial expansion [40].”
BackgroundTomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376
Jin, J., Shi, Y., Gong, J., Zhao, L., Li, Y., He, Q., & Huang, H. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1177-1 · Cited by 365
Causes and pathogenesis of focal segmental glomerulosclerosis
Fogo, A. B. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.216 · Cited by 360
Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome
Canaud, G., Bienaimé, F., Tabarin, F., Bataillon, G., Seilhean, D., Noël, L.-H., Dragon-Durey, M.-A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312890 · Cited by 355
Molecular pathways that drive diabetic kidney disease
Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P., & Susztak, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165654 · Cited by 341
“Recent studies have shown that complete ablation/ inhibition of mTORC1 in podocytes resulted in increased vulnerability and glomerulosclerosis, in contrast to the reported therapeutic health benefits of mTOR inhibitors or just genetic lowering of mTOR level (92).”
Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms
Gnudi, L., Coward, R. J. M., & Long, D. A. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.07.002 · Cited by 332
“44 Godel, M., et al. (2011) Role of mTOR in podocyte function and diabetic 552 nephropathy in humans and mice.”
BackgroundBidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling
Appenzeller-Herzog, C., & Hall, M. N. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.02.006 · Cited by 313
Self-citationImpaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy
Tagawa, A., Yasuda, M., Kume, S., Yamahara, K., Nakazawa, J., Chin-Kanasaki, M., Araki, H., Araki, S.-I., Koya, D., Asanuma, K., et al. (2016) · Diabetes · doi:10.2337/db15-0473 · Cited by 315
“Interestingly, mTORC1 activity has been reported to be enhanced in podocytes of humans and animals with advanced diabetic nephropathy (50,51), suggesting that some factors in diabetic serum may activate mTORC1, suppressing podocyte autophagy.”
BackgroundAutophagy in diabetic nephropathy
Ding, Y., & Choi, M. E. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0437 · Cited by 306
“The simultaneous deletion of both mTORC1 and mTORC2 in the mouse podocytes aggravated the glomerular lesions (Gödel et al. 2011).”
BackgroundDiabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury
Fakhruddin, S., Alanazi, W., & Jackson, K. E. (2017) · Journal of Diabetes Research · doi:10.1155/2017/8379327 · Cited by 292
“However, in podocytes of diabetic mice and patients, mTORC1 (mammalian target of rapamycin complex 1) is highly activated and may be involved in the mechanisms of diabetesinduced autophagy inhibition in podocytes [177].”
BackgroundLenoir, O., Jasiek, M., Hénique, C., Guyonnet, L., Hartleben, B., Bork, T., Chipont, A., Flosseau, K., Bensaada, I., Schmitt, A., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1049799 · Cited by 296
“inhibitor CDKN1B/p27 1 70 and MTOR activation.(50,71) Therefore, HG is expected to promote podocyte injury by perturbing cell cycle regulation, and promoting hypertrophy, dedifferentiation and apoptosis.”
BackgroundSelf-citationMechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
Bhattacharjee, N., Barma, S., Konwar, N., Dewanjee, S., & Manna, P. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.022 · Cited by 271
Emerging role of autophagy in kidney function, diseases and aging
Huber, T. B., Edelstein, C. L., Hartleben, B., Inoki, K., Jiang, M., Koya, D., Kume, S., Lieberthal, W., Pallet, N., Quiroga, A., et al. (2012) · Autophagy · doi:10.4161/auto.19821 · Cited by 253
“Genetic studies have begun to unveil the roles of the MTORC1-autophagy system in maintaining glomerular function.65-67 MTORC1 activity is enhanced in podocytes of diabetic animals as well as human DN. Specific activation of MTORC1 in podocytes recapitulates many DN phenotypes including glomerular membrane thickening,…”
BackgroundInfluentialSelf-citationMechanisms of podocyte injury and implications for diabetic nephropathy
Barutta, F., Bellini, S., & Gruden, G. (2022) · Clinical Science · doi:10.1042/cs20210625 · Cited by 221
“However, the complete ablation of mTORC1 activity in podocytes by Raptor deletion led to the early development of proteinuria in diabetic mice [235,236], indicating that while excessive mTORC1 activation is detrimental, basal mTORC1 activity is required for maintaining physiological functions of…”
Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?
Higgins, G. C., & Coughlan, M. T. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12503 · Cited by 250
“…that have shown that inhibition of mTOR activation protects against renal hypertrophy (Sakaguchi et al., 2006), glomerulosclerosis and proteinuria (Godel et al., 2011; Inoki et al., 2011), and mesangial expansion (Lloberas et al., 2006; Yang et al., 2007; Mori et al., 2009) in rodent models of…”
BackgroundAutophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential
Yang, D., Livingston, M. J., Liu, Z., Dong, G., Zhang, M., Chen, J.-K., & Dong, Z. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2639-1 · Cited by 252
“Moreover, complete lack of mTORC1 activity in podocyte-specific Raptor-deficient mice results in severe podocyte injury, glomerulosclerosis and proteinuria, underscoring the crucial importance of maintaining a tightly controlled mTOR signaling pathway to ensure normal renal function [73].”
BackgroundResearch Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy
Dai, H., Liu, Q., & Liu, B. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2615286 · Cited by 239
“In general, mature podocytes had to expand the size of themselves in order to compensate for glomerular dilation, which contributed to cover the denuded region of the GBM, because they were terminal-differentiated cells, which no longer are proliferated [14, 15].”
BackgroundEbrahim, N., Ahmed, I., Hussien, N., Dessouky, A., Farid, A., Elshazly, A., Mostafa, O., Gazzar, W., Sorour, S., Seleem, Y., et al. (2018) · Cells · doi:10.3390/cells7120226 · Cited by 235
“Also, the findings of the present study support the findings of Gödel et al. [22], who reported significant upregulation of mTOR itself and mTORC1 target genes in human patients with progressive DN, as compared to the controls.”
BackgroundResultThomanetz, V., Angliker, N., Cloëtta, D., Lustenberger, R. M., Schweighauser, M., Oliveri, F., Suzuki, N., & Rüegg, M. A. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201205030 · Cited by 221
Self-citationThe role of the podocyte in albumin filtration
Brinkkoetter, P. T., Ising, C., & Benzing, T. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.78 · Cited by 237
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease
Canaud, G., Bienaimé, F., Viau, A., Treins, C., Baron, W., Nguyen, C., Burtin, M., Berissi, S., Giannakakis, K., Muda, A. O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3313 · Cited by 222
Self-citationTherapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
Estrada, C. C., Maldonado, A., & Mallipattu, S. K. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018080853 · Cited by 221
Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury
Kim, E. N., Lim, J. H., Kim, M. Y., Ban, T. H., Jang, I.-A., Yoon, H. E., Park, C. W., Chang, Y. S., & Choi, B. S. (2018) · Aging · doi:10.18632/aging.101361 · Cited by 222
“Among them, the activation of mammalian target of rapamycin (mTOR) signaling pathway is involved in the pathogenesis for several kidney diseases, such as diabetic nephropathy [59].”
BackgroundRapamycin for longevity: opinion article
Blagosklonny, M. V. (2019) · Aging · doi:10.18632/aging.102355 · Cited by 205
“Furthermore, rapamycin reduces the incidence of diabetic complications such as diabetic nephropathy in rodents [42, 74-85].”
BackgroundObesity-Mediated Autophagy Insufficiency Exacerbates Proteinuria-induced Tubulointerstitial Lesions
Yamahara, K., Kume, S., Koya, D., Tanaka, Y., Morita, Y., Chin-Kanasaki, M., Araki, H., Isshiki, K., Araki, S.-I., Haneda, M., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012111080 · Cited by 213
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Self-citationMaezawa, Y., Takemoto, M., & Yokote, K. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12255 · Cited by 205
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
“The mechanism by which mTORi could affect glomerular permeability is not known, but recent experimental evidence showed that genetic deletion of mTORC1 in mouse podocytes induced proteinuria and progressive glomerulosclerosis, which highlights a central role for mTORC1 in the regulation of podocyte homeostasis and gen…”
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
Ricciardi, C. A., & Gnudi, L. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154890 · Cited by 190
Hu, C., Sun, L., Xiao, L., Han, Y., Fu, X., Xiong, X., Xu, X., Liu, Y., Yang, S., Liu, F., et al. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150625095407 · Cited by 199
“Interestingly, gene-dose reduction of mTOR complex 1 (mTORC1) in mouse podocytes was found to be associated with prevention of glomerulosclerosis and dampened the progression of diabetic nephropathy [84].”
BackgroundPodocytes: the Weakest Link in Diabetic Kidney Disease?
Lin, J. S., & Susztak, K. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0735-5 · Cited by 189
Unraveling the Role of Podocyte Turnover in Glomerular Aging and Injury
Wanner, N., Hartleben, B., Herbach, N., Goedel, M., Stickel, N., Zeiser, R., Walz, G., Moeller, M. J., Grahammer, F., & Huber, T. B. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050452 · Cited by 182
Self-citationHu, M., Wang, R., Li, X., Fan, M., Lin, J., Zhen, J., Chen, L., & Lv, Z. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13189 · Cited by 189
“By shuttling between the nucleus and the cytoplasm, SRSF1 interacted with and activated mTOR to promote translation [22, 23, 48]; dysregulation of the latter was sufficient to facilitate glomerular diseases [49].”
BackgroundMadhusudhan, T., Wang, H., Dong, W., Ghosh, S., Bock, F., Thangapandi, V. R., Ranjan, S., Wolter, J., Kohli, S., Shahzad, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms7496 · Cited by 181
“To further assess the pathophysiological relevance of ER-stress induction in human DN we next analysed gene expression (mRNA levels) in a large human renal database (Nephromine) 23,24 .”
The metabolic syndrome and chronic kidney disease
Zhang, X., & Lerman, L. O. (2017) · Translational Research · doi:10.1016/j.trsl.2016.12.004 · Cited by 173
“AMPK also inhibits activity of mammalian target of rapamycin, which mediates NOX4-induced podocyte injury,(111,112) thereby preventing kidney damage progression.(113,114) Furthermore, AngII not only increases mitochondrial production of ROS,(115) but may also promote mitochondrial degradation through the AT1-receptor,…”
Acute Kidney Injury and Progression of Diabetic Kidney Disease
Yu, S. M.-W., & Bonventre, J. V. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.12.005 · Cited by 175
Shukla, L., Yuan, Y., Shayan, R., Greening, D. W., & Karnezis, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00158 · Cited by 179
Update on diagnosis, pathophysiology, and management of diabetic kidney disease
Sugahara, M., Pak, W. L. W., Tanaka, T., Tang, S. C. W., & Nangaku, M. (2021) · Nephrology · doi:10.1111/nep.13860 · Cited by 171
Reiser, J., & Altintas, M. M. (2016) · F1000Research · doi:10.12688/f1000research.7255.1 · Cited by 179
González, N., Diabetes Cancer Connect Consortium, Prieto, I., del Puerto-Nevado, L., Portal-Nuñez, S., Ardura, J. A., Corton, M., Fernández-Fernández, B., Aguilera, O., Gomez-Guerrero, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14472 · Cited by 168
“mTOR inhibitors Several agents Yes Yes Yes No (Yes in non-DKD CKD) [98-99, 269]”
BackgroundRenal Protective Effects of Resveratrol
Kitada, M., & Koya, D. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/568093 · Cited by 170
“Among them, the activation of mammalian target of rapamycin (mTOR) signaling pathway is involved in the pathogenesis for several kidney diseases, such as diabetic nephropathy [65–67] and the autosomal dominant polycystic kidney disease [68].”
BackgroundBrinkkoetter, P. T., Bork, T., Salou, S., Liang, W., Mizi, A., Özel, C., Koehler, S., Hagmann, H. H., Ising, C., Kuczkowski, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.012 · Cited by 175
“The critical function of these processes has been demonstrated in various podocyte-specific knockout approaches targeting hypertrophy and actin remodeling (Gödel et al., 2011; Schell et al., 2013; Zschiedrich et al., 2017), all leading to a uniform pathological sequel involving foot process”
BackgroundSelf-citationInhibition of MTOR Disrupts Autophagic Flux in Podocytes
Cinà, D. P., Onay, T., Paltoo, A., Li, C., Maezawa, Y., De Arteaga, J., Jurisicova, A., & Quaggin, S. E. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070690 · Cited by 172
Growth-Dependent Podocyte Failure Causes Glomerulosclerosis
Fukuda, A., Chowdhury, M. A., Venkatareddy, M. P., Wang, S. Q., Nishizono, R., Suzuki, T., Wickman, L. T., Wiggins, J. E., Muchayi, T., Fingar, D., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030271 · Cited by 170
Self-citationThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Ong, P. S., Wang, L. Z., Dai, X., Tseng, S. H., Loo, S. J., & Sethi, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00395 · Cited by 162
“The two latter observations have been linked to its mTORC1 deactivating action independently of its mTORC2 inhibitory effects (Gödel et al., 2011; Lamming et al., 2012), suggesting that it may be possible to achieve a balance between the beneficial and detrimental effects of mTOR inhibition…”
BackgroundLü, Q., Ji, X., Zhou, Y., Yao, X., Liu, Y., Zhang, F., & Yin, X. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.006 · Cited by 167
“Recent studies have demonstrated that podocyte-specific mTORC1 activation recapitulats many DN features, such as podocyte loss, glomerular basement membrane thickening, mesangial expansion and proteinuria[16,17].”
BackgroundNovel targets of antifibrotic and anti-inflammatory treatment in CKD
Declèves, A., & Sharma, K. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.31 · Cited by 165
Nutrient Sensing, Autophagy, and Diabetic Nephropathy
Kume, S., Thomas, M. C., & Koya, D. (2012) · Diabetes · doi:10.2337/db11-0555 · Cited by 157
“knockout of mTORCs in podocyte are more severe than in single mTORC1 knockout; this supports the notion that mTORC2 exerts its protective role against podocyte injury induced by mTORC1 depletion (26).”
BackgroundInfluentialAutophagy in kidney disease and aging: lessons from rodent models
Lenoir, O., Tharaux, P.-L., & Huber, T. B. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.014 · Cited by 148
Self-citationDifferential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy
Bentzinger, C. F., Lin, S., Romanino, K., Castets, P., Guridi, M., Summermatter, S., Handschin, C., Tintignac, L. A., Hall, M. N., & Rüegg, M. A. (2013) · Skeletal Muscle · doi:10.1186/2044-5040-3-6 · Cited by 153
Self-citationZhang, M.-Z., Wang, Y., Paueksakon, P., & Harris, R. C. (2014) · Diabetes · doi:10.2337/db13-1279 · Cited by 151
“mTOR activity increases in podocytes in diabetic mice and correlates with increased ER stress and progressive glomerulosclerosis (31).”
BackgroundChoi, M. E. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034658 · Cited by 150
“Loss of podocyte function was further aggravated by overlapping genetic deletion of mTORC2 (114).”
BackgroundInfluentialKumar, P. A., Welsh, G. I., Saleem, M. A., & Menon, R. K. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00151 · Cited by 160
The podocyte as a target for therapies—new and old
Mathieson, P. W. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.171 · Cited by 147
Mammalian Target of Rapamycin Regulates Nox4-Mediated Podocyte Depletion in Diabetic Renal Injury
Eid, A. A., Ford, B. M., Bhandary, B., de Cassia Cavaglieri, R., Block, K., Barnes, J. L., Gorin, Y., Choudhury, G. G., & Abboud, H. E. (2013) · Diabetes · doi:10.2337/db12-1504 · Cited by 141
“Furthermore, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator hamartin (TSC1) recapitulated many diabetic nephropathy features, including podocyte loss, GBM thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice (35,36).”
BackgroundInflammation in kidney repair: Mechanism and therapeutic potential
Fu, Y., Yu, X., Li, H., Chen, A., & Dong, Z. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108240 · Cited by 148
AMPK/mTOR Signaling in Autophagy Regulation During Cisplatin-Induced Acute Kidney Injury
Wang, Y. X., Liu, Z., Shu, S., Cai, J., Tang, C., & Dong, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.619730 · Cited by 153
Barutta, F., Bellini, S., Kimura, S., Hase, K., Corbetta, B., Corbelli, A., Fiordaliso, F., Bruno, S., Biancone, L., Barreca, A., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2080382 · Cited by 141
Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
Liebau, M. C., Braun, F., Höpker, K., Weitbrecht, C., Bartels, V., Müller, R., Brodesser, S., Saleem, M. A., Benzing, T. R., Schermer, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063506 · Cited by 132
“Recent compelling evidence suggests that the tight regulation of autophagy is especially important in podocytes [19,20,21,22].”
BackgroundObesity, oxidative stress, and fibrosis in chronic kidney disease
Sharma, K. (2014) · Kidney International Supplements · doi:10.1038/kisup.2014.21 · Cited by 137
Kogot-Levin, A., Hinden, L., Riahi, Y., Israeli, T., Tirosh, B., Cerasi, E., Mizrachi, E. B., Tam, J., Mosenzon, O., & Leibowitz, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107954 · Cited by 126
Yasuda, M., Tanaka, Y., Kume, S., Morita, Y., Chin-Kanasaki, M., Araki, H., Isshiki, K., Araki, S.-I., Koya, D., Haneda, M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.001 · Cited by 123
“Growing evidence suggests that mTORC1 is pathologically activated in podocytes of the diabetic kidney in both humans and rodent models, and inactivation of mTORC1 ameliorated podocyte injury in diabetic nephropathy [33,34].”
Schaub, J. A., Alakwaa, F., McCown, P. J., Naik, A. S., Nair, V., Eddy, S. F., Menon, R., Otto, E. A., Demeke, D., Hartman, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164486 · Cited by 131
Self-citationInflammatory Mediators and Renal Fibrosis
Meng, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_18 · Cited by 129
Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy
Zhang, Y., Ma, K. L., Gong, Y. X., Wang, G. H., Hu, Z. B., Liu, L., Lü, J., Chen, P. P., Lu, C., Ruan, X. Z., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040368 · Cited by 126
Ryter, S. W., Bhatia, D., & Choi, M. E. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2018.7518 · Cited by 114
Wang, X., Gao, L., Lin, H., Song, J., Wang, J., Yin, Y., Zhao, J., Xu, X., Li, Z., & Li, L. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.009 · Cited by 114
“…mesangial matrix expansion and glomerulosclerosis and suppressed the development of DN in type 1 and 2 diabetic animals (Inoki et al., 2011; Gödel et al., 2011). mTORC1 is an important upstream inhibitor of autophagy, and Cina reported that mTORC1 is activated and may be involved in…”
BackgroundMesenchymal Stem Cell-Derived Extracellular Vesicles to the Rescue of Renal Injury
Birtwistle, L., Chen, X.-M., & Pollock, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126596 · Cited by 113
“The mechanistic target of rapamycin (mTOR) is a nutrient-sensing protein kinase that suppresses autophagy and exacerbates podocyte damage in CKD, and its deactivation represents a target for MSC-exosomes [171,172].”
BackgroundAutophagy Function and Regulation in Kidney Disease
Kaushal, G. P., Chandrashekar, K., Juncos, L. A., & Shah, S. V. (2020) · Biomolecules · doi:10.3390/biom10010100 · Cited by 116
“Moreover, the upregulation of mTOR activity has been documented in the renal IR model of AKI [78], a rat model of subtotal nephrectomy [79], glomerular injury, including diabetic nephropathy [80,81], and polycystic kidney disease [82].”
BackgroundRegulation of TFEB activity and its potential as a therapeutic target against kidney diseases
Zhang, W., Li, X., Wang, S., Chen, Y., & Liu, H. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0265-4 · Cited by 119
Autophagy as a Therapeutic Target in Diabetic Nephropathy
Tanaka, Y., Kume, S., Kitada, M., Kanasaki, K., Uzu, T., Maegawa, H., & Koya, D. (2012) · Experimental Diabetes Research · doi:10.1155/2012/628978 · Cited by 111
“Finally, podocyte-specific Raptor-heterozygous mice show partial deletion of mTORC1 activity in podocyte and resistance to the development of diabetic nephropathy in both STZ-induced type 1 diabetic mice [68] and type 2 diabetic db/db mice [69].”
BackgroundmTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress
Grahammer, F., Haenisch, N., Steinhardt, F., Sandner, L., Roerden, M., Arnold, F., Cordts, T., Wanner, N., Reichardt, W., Kerjaschki, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402352111 · Cited by 109
“Furthermore, mTORC2 deficiency alone did not show any morphological or functional abnormalities under baseline conditions, suggesting that mTORC2 partially compensates for and reduces pathophysiological disturbances caused by RAPTOR/mTORC1 deficiency, potentially by increasing AKT prosurvival signaling (32, 33).”
BackgroundSelf-citationGene–Gene and Gene–Environment Interactions in Apolipoprotein L1 Gene-Associated Nephropathy
Freedman, B. I., & Skorecki, K. L. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01330214 · Cited by 113
Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201600293r · Cited by 104
“This is consistent with previous studies that have shown that mTOR is activated in podocytes in diabetic nephropathy (51, 52).”
ResultNutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases
Huynh, C. Q., Ryu, J., Lee, J., Inoki, A., & Inoki, K. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00648-y · Cited by 117
Self-citationAutophagy in Diabetes: β-Cell Dysfunction, Insulin Resistance, and Complications
Barlow, A. D., & Thomas, D. (2015) · DNA and Cell Biology · doi:10.1089/dna.2014.2755 · Cited by 118
“Conversely, podocyte-specific reduction of mTOR reduced the severity of diabetic renal disease in obese mice (Godel et al. , 2011; Inoki et al. , 2011).”
New Insights into Podocyte Biology in Glomerular Health and Disease
Assady, S., Wanner, N., Skorecki, K. L., & Huber, T. B. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017010027 · Cited by 111
Self-citationAutophagy in Kidney Health and Disease
Wang, Z., & Choi, M. E. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5363 · Cited by 100
“Conversely, reduction of mTORC1 activity in podocytes by deletion of one allele of Raptor gene in diabetic mice prevented the development of diabetic nephropathy (24, 28).”
Metadata
- Authors
- Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., Wiech, T., Fornoni, A., Nelson, R. G., Kretzler, M., Wanke, R., Pavenstädt, H., Kerjaschki, D., Cohen, C. D., Hall, M. N., Rüegg, M. A., Inoki, K., Walz, G., & Huber, T. B.
- Affiliations
- University of Freiburg (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Zurich (CH)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) (DE)
- University of Miami (US)
- National Institutes of Health (US)
- University of Münster (DE)
- Medical University of Vienna (AT)
- University of Basel (CH)
- Life Sciences Institute (SG)
- Corresponding author
- Huber, Tobias B.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2197-2209
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104746
- OpenAlex
- W2051719011
- Cited by
- 547
- References
- 62
- Citations by year
- 2026: 22 · 2025: 23 · 2024: 28 · 2023: 36 · 2022: 30 · 2021: 43 · 2020: 50 · 2019: 39 · 2018: 40 · 2017: 34 · 2016: 38 · 2015: 36 · 2014: 40 · 2013: 47 · 2012: 25
- FWCI
- 31.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (122439)
- National Institutes of Health (5r01dk083491-09)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, P30DK081943, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mTOR, mTORC1, mTORC2, podocytes, diabetic nephropathy, glomerulosclerosis, proteinuria, glomerular hypertrophy, hyperfiltration, mTOR inhibition, glomerular disease, gene deletion
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Rapamycin-Insensitive Companion of mTOR Protein, Adult, Animals, Carrier Proteins, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Humans, Kidney Glomerulus, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Transgenic, Nephrosis, Lipoid, Proteins, Proteinuria, Transcription Factors, Trans-Activators, Mice, Knockout, Disease Progression, Gene Dosage, Genetic Predisposition to Disease, Sirolimus, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.